LONG MINI-FUTURE - MODERNA | Market Closed - Euronext Paris 10:00:00 14/06/2024 pm IST | ||
| 4.605 EUR | -11.44% |
|
| Current month | -1.85% | ||
| 1 month | +30.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 4.785 | -8.68% |
| 13/24/13 | 5.24 | -2.24% |
| 12/24/12 | 5.36 | -1.65% |
| 11/24/11 | 5.45 | +2.06% |
| 10/24/10 | 5.34 | -8.25% |
Real-time Euronext Paris
Last update June 14, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| TS69V | |
| ISIN | DE000VD1BG88 |
| Date issued | 07/03/2024 |
| Strike | 90.95 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.44 € |
|---|---|
| Lowest since issue | 0.785 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- TS69V Certificat
